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374Purification of CD41 T Cells for Adoptive
Immunotherapy after Allogeneic Hematopoietic
Stem Cell Transplantation
Evgeny Klyuchnikov,1 Andreas Sputtek,2 Olga Slesarchuk,1,3 Michael Lioznov,1
Thomas Stu¨big,1 Ulrike Bacher,1 Gitta Amtsfeld,1 Edeltraut Merle,2 Marie-Luise Reckhaus,2
Boris Fehse,1 Christine Wolschke,1 Raissa Adjalle´,1 Francis Ayuk,1
Axel Zander,1 Nicolaus Kro¨ger1Donor lymphocyte infusions (DLIs) are used for adoptive immunotherapy to prevent or treat relapse and
infectious complications after allogeneic hematopoietic stem cell transplantation (HSCT). Unmanipulated
DLIs are associated with a risk of graft-versus-host disease (GVHD), probably related to CD81 T cell activity.
We investigated an automated clinical-scale human-CD41-cell purification method to deplete CD81 cells.
Twenty-four stem cell recipients received a total of 24 leukapheresis products being enriched for CD41 cells
using magnetic associated cell sorting (MACS) with an automated device (CliniMACS) before DLIs. MACS
resulted in a mean CD41 cell count of 16  106/kg bw corresponding to 3.4-fold CD41 cell enrichment.
Mean yield and purity of CD451CD31CD41CD1427AAD2were 74%6 23% and 82%6 11%, respectively.
Median initial dose of DLIs was 1.1  106 CD41/kg. During a median follow-up of 25 months, 7 (30%)
patients experienced GVHD (acute II-IV: n 5 4, 17%; acute III-IV: n 5 2, 8%; chronic limited: n 5 2, 8%;
chronic extensive: n 5 1, 4%). Thirteen of 21 further evaluable patients (62%) showed measurable clinical
response, 2 patients with therapy refractory infectious complications (HSV) showed remarkable immuno-
logic improvement. Automated enrichment of CD41 by magnetic cell sorting provides an efficient and rapid
method for processing donor lymphocytes. Additional studies should further investigate this approach in
terms of efficacy and the risk of GVHD.
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exerted by donor T cells [1-3]. Based thereon, donor
lymphocyte infusions (DLIs) provide an effective
adoptive approach to treat and prevent relapses
after HSCT [4,5]. However, unmanipulated DLIs
(uDLIs) were found to be associated with an
increased incidence of graft-versus-host disease
(GVHD) (from 13% to 64%), which might be fatal
in some cases [5]. To reduce the incidence of this
event, several strategies such as delaying the transfer
and/or escalating the dose of donor lymphocytes, or
selected infusion of defined subpopulations of donor
lymphocytes, have been investigated [6-10].
Because there is evidence that donor-derivedCD81
T cells play an important role in the development of
acute GVHD (aGVHD) [11], several monoclonal
antibody-based strategies (eg, lysis of CD81 cells after
addition of complement or immunomagnetic-based
separation methods) to selectively deplete this subpop-
ulation have been proposed [12-14]. Some previous
studies have already reported the feasibility of CD81
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[12,13,15,16]. However, residual contamination of the
product with CD81 cells in many of these studies
complicates evaluation of the true efficacy of
transferred donor CD41 cells regarding the direct
mediation of the GVL effect.
In the current study, we applied a selection of
CD41 cells using the CliniMACS device to evaluate
safety and efficacy of CD41-selected DLIs being ad-
ministered because of residual/persistent disease or
preemptively (eg, in case of mixed donor chimerism)
in recipients of HSCT with different hematologic
malignancies.PATIENTS AND METHODS
Patients’ Characteristics
We retrospectively evaluated 24 patients (15
males, 9 females) with different hematologic entities
who received CD41-enriched DLIs after HSCT in
the period 2005 to 2009 at the University of Hamburg.
The median age was 49 years (range: 21-65 years). A
total of 11 patients had multiple myeloma (MM), 1 pa-
tient had chronic lymphocytic leukemia (CLL),
whereas the remaining 12 patients had different mye-
loid malignancies: primary/secondary myelofibrosis
(MF, n 5 6); chronic myelog leukemia in chronic
phase (CML-CP, n 5 3); myelodysplastic syndromes
(MDS, n 5 2; MDS/myeloproliferative neoplasm
(MPN) overlap, n 5 1).
Indication for the application of CD41-selected
DLIs was relapse or refractory disease in the majority
of patients (n5 18): morphologic relapse (n5 7), mo-
lecular relapse (n 5 6; in detail: MF with a positive
JAK2V617F mutation status, n 5 4; CML with an in-
creased BCR-ABL1/ABL1 ratio, n 5 2), stable/pro-
gressive disease (MM, n 5 4), evidence of minimal
residual disease (MM with positive immunofixation,
n 5 1). Four patients received CD41 DLIs because
of an increased relapse risk based on the persistence
of mixed donor chimerism (CML, n 5 1; MDS, n 5
2; MM, n 5 1). In the remaining 2 patients (MM,
n5 1; CLL, n5 1), the indication to CD41 cell ther-
apy was delayed immunologic recovery of CD41 cell
counts in association with severe refractory herpes
simplex virus (HSV) infection.Characterization of Transplantations
Most patients (n5 19; 79%) received dose-reduced
conditioning (RIC), consisting of fludarabine (Flu; cu-
mulative doses, 90 mg/m2)/melphalan (140 mg/m2;
n5 6), busulfan (Bu; 8mg/kg orally [p.o.] or equivalent
intravenously [i.v.])/Flu (150 mg/m2; n 5 6),
“FLAMSA” (Flu, 120 mg/m2; cytarabine, 8000 mg/
m2; amsacrine, 400 mg/m2) with Bu (n 5 3), or withtotal-body irradiation (4Gy, n 5 2) and treosulfan (30
g/m2)/cyclophosphamide (120 mg/kg)/etoposide (30
mg/m2) (n 5 2). The 5 remaining patients (21%)
underwent HSCT after standard (myeloablative) con-
ditioning, consisting of Bu (16 mg/kg orally or equiva-
lent i.v.) and cyclophosphamide (120 mg/kg).
Thirteen patients received allografts from unre-
lated HLA-matched (n 5 8; 8/8 single allele match)
or mismatched (n 5 5; alleles: A, C, DRQB1) donors.
Eleven patients received the allografts from HLA-
identical siblings. Following HSCT, 9 patients
(38%) experienced aGVHD (grade II-IV) and 7
(29%) chronic limited GVHD (cGVHD).
All patients gave written informed consent for
CD41 DLIs therapy and for the use of data for scien-
tific purposes. The study was performed in accordance
with the Declaration of Helsinki.METHODS
Cell Collection and CD41 Cell Selection
Before performing CD41 cell selection, mononu-
clear cells (MNCs) were collected (in 9 cases at our in-
stitution using the manual MNC program of a COBE
Spectra Apheresis System, CaridianBCT, Garching,
Germany; in 15 cases at other institutions). Conse-
quently, the enrichment of CD41 cells was performed
for all 24 products at the Institute for Transfusion
Medicine, University Medical Center Hamburg-
Eppendorf. Enrichment was realized by labeling of
CD41 expressing cells with CliniMACS CD41 Mi-
croBeads (no. 304-01, P/N 130-030-401). Subse-
quently, the magnetically labeled CD41 cells were
separated according to the manufacturer’s instructions
(Miltenyi Biotec GmbH, Bergisch-Gladbach, Ger-
many) using the Magnetic Associated Cell Sorting
(MACS) cell separation technology. In a first step,
the labeled cells are retainedmagnetically on a column,
whereas the unlabeled (CD4-negative) cells pass
through. After removal of the magnetic field the target
cells can be collected by elution from the column.
Flow cytometry
Subsequently, samples from the different cell frac-
tions were analyzed by fluorescence-activated cell sort-
ing (FACS): (1) the leukapheresis product after labeling
with CD451CD31CD41 antibodies and washing be-
fore separation (“original fraction”), (2) the enriched
CD31CD41 cell fraction after the CliniMACS separa-
tion (“positive fraction”), the nontarget cell fraction
after CliniMACS separation (“negative fraction”).
Total numbers of nucleated blood cells (TNC) in the
samples were determined on the Sysmex F-800 cell
counter (Sysmex, Kobe, Japan). Samples of each frac-
tion (approximately 1  106 TNC in 100 mL/test)
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dark with the different combinations of the following
fluorochrome-conjugated mouse antihumanmonoclo-
nal antibodies: Miltenyi Biotec GmbH (Bergisch-
Gladbach, Germany): CD3-FITC, CD4-PE, CD8-PE,
CD45-APC; Becton Dickinson GmbH (Heidelberg,
Germany): CD14-PerCP, CD19-FITC, CD25-PE,
CD56-PE; and eBioscience GmbH (Frankfurt am
Main, Germany) CD127-PerCP. Data acquisition
and evaluation were performed with a FACS Calibur
4-color dual-laser flow cytometer according to the
manufacturer’s manual program (Becton Dickinson
GmbH; Heidelberg, Germany). The following defini-
tions have been used: the purity of CD41 enrichment
was defined as percentage of CD451CD31CD41
CD1427AAD2 cells in the positive fraction. To calcu-
late the enrichment of CD41 cells the percentage of
CD451CD31CD41CD1427AAD2 cells in the posi-
tive fraction was divided by the percentage of
CD451CD31CD41 cells in the original fraction.
The yield of CD41 cells was obtained by dividing
the total number of CD41 cells in the positive fraction
by the total number of CD41 cells in the original
fraction.
Additionally, the percentage of the following cell
fractions was determined in 7 patients: (1) CD451
CD31CD81 cells, (2) CD451CD41CD81 cells, (3)
CD451CD32CD561 cells, (4) CD451CD191 cells,
and (5) CD451CD41CD251CD127low cells.Evaluation of response to application
of CD41 DLIs
InMMpatients, the international criteria [17] with
additional estimation of k/l free-light chain ratio and
patient-specific ASO-primers [18] were used to assess
the response. Patients with MF were monitored
according to the International Working Group
(IWG) consensus criteria [19], combined with surveil-
lance of chimerism [20,21] and measurement of the
JAK2V617F mutation load [22,23]. The MDS
patients were monitored according to the IWG
criteria being published by Cheson et al. [24] with ad-
ditional measurement of chimerism [20,21] and the
JAK2V617F mutation load [22,23] in 1 patient with
MDS/MPN overlap. For CML, the BCR-ABL1/
ABL1 ratio was monitored according to European
Leukemia Net (ELN) guidelines [25].
One CML patient received CD41 DLIs after he
had already achieved complete molecular remission
(mCR) following previous combined therapy with
uDLIs and imatinib. Thus, only 23 of 24 patients
were evaluable for response to CD41 DLI therapy
within the study. For patients with severe HSV infec-
tion, clinical improvement was postulated based on the
dynamics of clinical, virologic, and immunologic pa-
rameters.RESULTS
CD41 Enrichment
Before enrichment, the apheresis products (n5 24)
were containing a mean of 74.9  108 TNC (range:
38.1-162.2) and 14.2  108 CD41 cells (range: 3.7-
25.6). AfterMACS enrichment, the mean CD41 count
reached 12.2 108 (range: 4.7-24.9), reflecting a recov-
ery rate of 74%6 23%. The relative amount of CD41
T cells (purity) increased from a mean value of 24.9%
(range: 6.6%-42.5%) in the original fraction to a mean
of 82%6 11%, that is, by a factor of more than 3. Cal-
culated per kilogram body weight (bw), a mean of 16
106 CD41 cells was obtained after MACS procedure
(Table 1). Additionally, to investigate the specificity
and sensitivity of CD41-enrichment, we estimated
the amounts of some other subpopulations of immune
cells: CD31CD81T cells, NK (CD32CD561) cells, B
(CD191), and T regulatory (CD41CD251CD127low)
cells. After CD41-enrichment, the median amounts of
B and NK cells decreased from 11.5% to 0.2%, and
from 7.2% to 0.01%, respectively. In contrast, because
of CD4-positivity, the amount of T regulatory cells
(CD41CD251CD127low) increased from 1.4% to
4.8%. CD81 cells were not totally removed during
the procedure, as we observed a reduction from
12.6% to 0.99% only. We performed supplementary
measurements and observed that these cells were
corresponding to CD41CD81 double-positive cells
(individual data not shown).Application of CD41 DLIs
In the absence of GVHD, immunosuppressive
medication was stopped at least 2 weeks before the ap-
plication of CD41-selected DLIs. The latter were only
applied if there was no evidence of activeGVHD. After
thawing, DLI products were infused i.v. over a 10 to
15-minute period in the outpatient department. No
prophylactic immunosuppressive medication was
administered afterCD41DLIs. The initial administra-
tion of CD41 lymphocytes was performed at a median
of 14 months (range: 1-76) after HSCT. The median
dose of the infused cells was 1.1  106 CD41/kg bw
(range: 1.1-15). The cell dose was higher in the recip-
ients of related (4.5  106/kg bw; range: 1-15) when
compared to the recipients of unrelated transplantation
(2.3  106/kg bw; range: 1-10; independent t-test, P\
.005). A total of 12 patients underwent additional phar-
macotherapy, including immunomodulating agents
(thalidomide, lenalidomide) and/or bortezomib in
MM patients (n5 8); tyrosine kinase inhibitors (imati-
nib, dasatinib) in CML patients (n 5 3); and acyclovir
and foscavir for a patient with delayed immune
recovery with concomitant HSV infection (Table 2).
Table 1. CD4+ MACS Enrichment
Before MACS After MACS
No. CD4+ (%) CD4+ (108) CD4+ (%) CD4+ (108/kg bw) CD4+ (106/kg bw) CD4+-Enrichment (Times) Yield (%)
1. 6.6 3.7 53.7 4.73 5.03 3.3 >95
2. 20.2 10.7 75.6 7.50 8.43 3.8 70
3. n.a. n.a. 65.2 10.99 13.92 3.2 n.a.
4. n.a. n.a. 88.0 12.34 14.35 n.a. n.a.
5. 17.9 14.4 75.3 7.49 10.71 4.2 52
6. 34.4 16.4 89.3 12.42 18.26 2.6 76
7. 27.0 10.3 73.8 6.97 8.09 2.8 68
8. 42.5 25.6 89.0 10.27 15.56 2.1 40
9. 8.8 6.5 62.1 5.06 7.32 7.1 78
10. n.a. n.a. 81.8 10.23 11.37 n.a. n.a.
11. n.a. n.a. 87.9 8.68 10.22 n.a. n.a.
12. 25.9 18.6 94.5 15.76 18.32 3.7 85
13. n.a. n.a. 92.2 24.93 36.13 n.a. n.a.
14. 20.4 9.6 79.6 6.87 7.23 3.4 72
15. 32.7 13.9 84.7 12.85 17.60 2.6 93
16. 35.2 17.1 78.7 8.31 11.70 2.3 49
17. n.a. n.a. 85.5 19.99 34.47 n.a. n.a.
18. 30.5 25.0 87.0 13.66 18.21 2.9 55
19. n.a. n.a. 95.0 15.92 19.41 n.a. n.a.
20. 30.7 17.4 87.0 17.41 27.20 2.8 >95
21. n.a. n.a. 92.6 16.88 16.08 n.a. n.a.
22. n.a. n.a. 91.6 24.86 30.32 n.a. n.a.
23. 16.3 8.95 72.2 6.87 7.72 4.5 77
24. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Mean 24.9 14.2 81.8 12.22 15.98 3.4 74
Min 6.6 3.7 53.7 4.7 5.0 2.1 40
Max 42.5 25.6 95.0 24.9 36.1 4.5 >95
SD 10.4 6.4 10.7 5.7 8.7 1.2 23
No. indicates patients’ number; MACS, magnetic associated cell sorting; n.a., not available; bw, body weight; Min, minimal value; Max, maximal value;
SD, standard deviation.
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The overall response rate was 65% (15/23 patients,
in whom response could be assessed). In more detail, 5
of 6 patients (83%) with morphologic relapse showed re-
sponse to CD41 application (MF, n 5 2; MM, n 5 2;
MDS/MPN, n 5 1). Of note, in this subgroup, 3 pa-
tients with JAK2V617F mutated disease (MF, n 5 2;
MDS/MPN, n5 1) who had signs of morphologic re-
lapse achieved mCR. The sixth patient with morpho-
logic relapse (MM) achieved partial remission (PR).
Four of 6 cases (67%) with molecular relapse (MF,
n 5 2; CML-CP, n 5 2) achieved mCR. One of 4 pa-
tients with stable/progressive MM achieved PR (25%).
Two of 4 patients who received CD41-selected DLIs
because of mixed chimerism (MDS, n 5 1; MM, n 5 1)
converted to complete donor chimerism. Both patients
with severe infectious complications showed clinical
improvement (Table 2; Figure 1).
Duration of response
Response was stable in 33% (5/15) of responding
patients: relapsed MM (n 5 1); relapsed MF (n 5 2);
mixed chimerism by MDS (n 5 1); and poor immune
function (n 5 1). All of these patients remained in
CR/mCR lasting up to a median of 22 months (range:
4-46) from the initial infusion.In the remaining 10 patients (67%), the initial
response was followed by disease progression after
a median of 5 months (range: 3-9). These patients sub-
sequently received either uDLIs (n 5 4) or CD41-en-
riched (n 5 6) DLIs in a dose-escalated regimen. The
latter subgroup received a median dose of 6.2  106
CD41/kg bw (range: 5.0-10.0). Four of 6 patients
(67%) showed response to this second CD41 application
after a median of 4 months (range: 2-8). Responses
were stable in 3 of 4 responders (MM, MF, and
CML patients). At the time of the report, the patients
were alive and in CR/mCR 10, 12, and 40months from
the initial CD41 infusion.
After a median follow-up of 32 months (range: 10-
54) from the initial administration of manipulated
DLIs, all 10 patients who showed a transient response
and received a second application of either CD41
DLIs or uDLIs were alive (complete remission [CR],
n 5 4; mCR, n 5 4; very good partial remission
[VGPR], n5 1; clinical improvement, n5 1; Table 2).
Refractory patients
Eight patients, who were refractory to the initial
administration of CD41 DLIs, underwent a subse-
quent DLI therapy at a median of 4 months (range:
3-8) from the first application. Of those, 3 patients
Table 2. Patients’ Characteristics and Outcomes following CD4+ DLI Therapy
No. Sex/Age Diagnosis Donor
Reason for
CD4+ DLIs
Interval
SCT-CD4+
DLIs
(Months)
Dose
(/kg bw)
No. of
CD4+ DLI
Acute
GVHD
Chronic
GVHD
Response
to the 1st
CD4+ DLIs
Additional
therapy to
the First
CD4+ DLIs
Actuarial
Status from
1 CD4+ DLIs
(Months)
1. m/40 MM MUD PD 34 1106 2 d d No/PD Thal, Bor, Len dead (22, PD)
2. f/45 MM MUD Rel 14 1106 1 d d No/PD Len alive (7, PD)
3. f/51 MM Sibling SD 76 1.5107 1 d d No/SD no alive (23, CR)
4. f/65 MM Sibling MRD+ 28 5106 1 grade II d No/PD Len alive (21, VGPR)
5. f/47 MM MMUD HSV 2 1106 1 d d No/CI no alive (54, VGPR)
6. m/32 MM MUD Rel 39 1106 2 d d Yes/CR Bor, Thal alive (52, CR)
7. m/49 MM Sibling Rel 14 1106 1 grade II d Yes/CR Bor alive (46, CR)
8. f/49 MM Sibling Proph 5 5106 2 d d Yes/CDC no alive (30, CR)
9. m/60 MM Sibling Rel 46 5106 2 d d Yes/PR Len alive (26, CR)
10. m/41 MM MUD SD 11 1106 2 grade III d Yes/PR Len alive (21, VGPR)
11. m/48 MM Sibling SD 11 5106 2 d d No/SD Len alive (10, CR)
12. m/53 MF Sibling MRel 36 1106 2 d limited Yes/mCR no alive (40, mCR)
13. m/50 MF Sibling MRel 13 5106 1 d d No/SD no alive (12, mCR)
14. m/51 MF MMUD Rel 48 1106 2 d d Yes/mCR no alive (35, mCR)
15. f/33 MF MUD MRel 34 1.2106 1 d d Yes/mCR no alive (21, mCR)
16. m/55 MF MMUD MRel 6 1.5106 1 d extensive No/SD no alive (30, CR)
17. f/60 MF MUD Rel 4 5106 1 grade III d Yes/mCR no alive (20, mCR)
18. f/36 MDS MMUD Proph 6 5106 2 d d No/MC no alive (13, Rel)
19. m/64 MDS MMUD Proph 14 1106 1 d limited Yes/CDC no alive (21, CR)
20. m/42 MDS/MPN MUD Rel 17 1.2106 2 d d Yes/mCR no alive (16, mCR)
21. m/21 CML-CP Sibling Proph 73 1106 1 d d n.e. IM alive (21, mCR)
22. m/37 CML-CP Sibling MRel 29 5106 2 d d Yes/mCR IM alive (12, mCR)
23. m/56 CML-CP Sibling MRel 8 1106 1 d d Yes/mCR DAS alive (52, mCR)
24. f/58 CLL MUD HSV 1 0.1106 1 d d Yes/CI Acic, Fos alive (4, CR)
No. indicates number; m, male; f, female; PCM, plasma cell myeloma; MF, myelofibrosis; CML-CP, chronic myelogenous leukemia (chronic phase); MDS,
myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; SCT, allogeneic
stem cell transplantation; uDLIs, unmanipulated donor lymphocyte infusions; PD, progressive disease; SD, stable disease; CI, clinical improvement; CDC,
achievement of complete donor chimerism; MC, persistence of mixed chimerism; HSV, Herpes simplex virus infection; n.e., not evaluable; bw, body
weight; GVHD, graft-versus-host disease; Rel, clinical/histopathologic relapse; MRel, molecular relapse; MRD+, minimal residual disease positive; Proph,
preemptive administration; Thal, thalidomide; Bor, bortezomib; Len, lenalidomide; Acic, aciclovir; Fos, foscarnet; IM, imatinib; DAS, dasatinib; VGPR,
very good partial remission; CR, complete remission; mCR, complete molecular remission.
378 Biol Blood Marrow Transplant 17:374-383, 2011E. Klyuchnikov et al.(morphologic relapse of MF, n 5 1; progressed MM,
n 5 1; preemptive MDS, n 5 1) received CD41-
selected infusions. An amount of 5.6  106 CD41/kg
bw cells (range: 2.0-10.0) was applied. Response
(MF, mCR, n 5 1) was observed within 4 months
from the infusion and lasted up to 21 months, followed
by disease progression (Figure 1). All 8 patients re-
quired additional treatment, which included drug
therapy and additional infusions (1-3 times) of uDLIs.
Response Regarding the Presence of
Concomitant Drug Therapy
Response in patients who received CD41 DLIs
only
In 12 patients with morphologic (MF, n 5 2;
MDS, n 5 1) or molecular relapse (MF, n 5 4), pro-
gressed/stable disease (MM, n 5 1), mixed chimerism
(MM, n 5 1; MDS, n 5 2), and severe viral infection
(n 5 1) CD41-enriched DLIs were given at a median
of 16 months (range: 2-48) from HSCT without any
concomitant therapy. The median dose was 2.6 
106 CD41/kg bw (range: 1-5). Responses were docu-
mented in 8 patients (67%): 6 relapsed patients (mor-
phologic: MF, n5 2;MDS, n5 1; molecular: MF, n5
2; MDS, n 5 1) achieved mCR; 1 patient with MM
converted from mixed to complete donor chimerism(MM, n 5 1); and 1 patient with severe viral infection
demonstrated clinical improvement (Figure 2).
Response in patients who received CD41 DLIs
combined with drug therapy
The 12 remaining patients underwent concomi-
tant drug therapy being employed either simulta-
neously (n 5 7) or after (n 5 5) the CD41-selected
infusions. The median CD41-cell dose being used in
this setting was 2.2  106/kg bw (range: 0.1-5). Re-
sponses were observed in 7 of 11 evaluable patients
(64%): relapsed MM (CR, n 5 2; PR, n 5 1), CML-
CP in molecular relapse (mCR, n 5 2), stable disease
of MM (PR, n 5 1), and severe HSV infection
(Table 2 and Figure 2).GVHD
The designations of aGVHD and cGVHD were
based on the time interval from the initial DLIs admin-
istration point. During the wholemedian follow up pe-
riod of 25 months (range: 4-54), 7 patients (30%)
showed signs of GVHD (aGVHD grade II-IV, n 5
4; aGVHD grade III-IV, n 5 2; 17%; cGVHD lim-
ited, n5 2; 8%; cGVHD extensive, n5 1; 4%), which
required an adequate immunosuppression. Of those 7
patients, 3 were transplanted from related, 4 from
Figure 1. Results of initial CD41-selected cell infusions (DLIs, donor lymphocyte infusions; CML, chronic myelogenous leukemia in chronic phase; HSV,
herpes simplex virus; MDS, myelodysplastic syndromes; CR, complete remission; mCR, complete molecular remission; PR, partial remission; CDC,
complete donor chimerism; CI, clinical improvement; GVHD, graft-versus-host disease.)
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mismatched, n 5 2). Importantly, 13 of 16 patients
(81%) with a history of aGVHD grade II-IV or
cGVHD either after HSCT or after previously admin-
istered unmanipulated DLIs, developed no GVHD af-
ter the first application of CD41-selected DLIs. More
detailed, GVHD was observed in 6 of 24 patients
(25%; aGVHD, n 5 4; cGVHD, n 5 2) after first,Figure 2. Outcomes for CD41-cells recipients regarding the presence of co
lodysplastic syndrome; CML, chronic myelogenous leukemia in chronic phase; H
ical improvement; CDC, complete donor chimerism; GVHD, graft-versus-hosand in 1 of 9 (11%, chronic limited) after second
CD41 cell infusion, respectively. Interestingly, 2 pa-
tients who received higher amounts of double
CD41CD81 positive cells (0.83% and 1.59%, respec-
tively), experienced severe aGVHD (grade III).
Of note, the response to CD41 application seemed
to be associated to the development of GVHD: 6 of 15
patients (40%) showing response to the first CD41ncomitant drug therapy. (DLIs, donor lymphocyte infusions; MDS, mye-
SV, herpes simplex virus; mCR, complete molecular remission; CI, clin-
t disease.)
380 Biol Blood Marrow Transplant 17:374-383, 2011E. Klyuchnikov et al.application developed either aGVHD (grade II-IV,
n 5 4; grade III-IV, n 5 2) or limited cGVHD (n 5
2). In contrast, 8 patients with no response experienced
neither aGVHD nor cGVHD. This, however, did not
reach statistical significance (Fisher’s exact test; P .
.05).
Survival Outcomes
After a median follow up of 25 months (range:
4-54) from the first CD41 DLIs administration, all
but 1 patients were alive (n 5 23/24). There were no
cases of infusion-related toxicity and treatment-
related mortality. One patient with MM, who re-
mained resistant to adoptive immunotherapy died 22
months from the initial CD41 DLI time-point be-
cause of disease progression. The 2-year overall (OS)
and disease- free survival (DFS) for all patients was
91% (95% confidence interval [CI]: 73%-100%) and
82% (95% CI: 63%-100%; Kaplan-Meier method;
Figure 3), respectively.
Seventeen of 21 patients (80%) who were alive and
received CD41DLIs because of disease persistence or
preemptively, were in CR (including mCR in 7 pa-
tients), 2 (10%) in VGPR, and 2 patients (10%) either
relapsed or experienced disease progression at the last
follow-up (Table 2).DISCUSSION
Although we were able to demonstrate some
evidence of the clinical efficacy and safety of CD41-
selected DLIs, it seems difficult to recommend this
approach as an alternative option to uDLIs in sight
of some key limitations of the study: the limited and
heterogeneous cohort of patients, various indications
to treatment, and presence of additional therapy.Figure 3. The incidence of disease-free survival (DFS) following the
CD41-selected infusions.First, we evaluated the purity and cell recovery
rates following the CD41-enrichment using the Clin-
iMACS device.We observedmean purity and recovery
rates of .80% and .70%, respectively. Also, quality
and quantity of CD41 cells were sufficient for the pres-
ervation and the performance of additional applica-
tions of manipulated DLIs in 11 of 24 patients
(38%). Cell processing had apparent negative impact
on neither cell viability nor on the efficacy of the pro-
cedure, because infusion of 1  106 CD41/kg bw was
effective and not associated with acute transfusion-
associated toxicity. Further, there was a significant
reduction of CD81 T, natural killer (NK), and B cells
after the procedure. It should be mentioned that also
double-positive CD41CD81 cells were positively
selected. Although generally the CD41CD81 double-
positive cells are suggested to be an immature lympho-
cyte subpopulation undergoing both positive and
negative selection in thymus, some studies revealed
heterogeneity of these cells [26-29]. Some authors
showed an association of increased CD41CD81
double-positive cell numbers with autoimmune and
infectious diseases [30-34]. Further, Bagot et al. [35]
documented a capacity of CD4hiCD8low double-
positive cells to exert a tumor-specific MHC class I
restricted cell lysis [35].
Second, we focused on the clinical efficacy of the
CD41 selected DLIs. Response was documented in
15 of 23 evaluable patients (65%). In the majority of
patients, the median duration of response was no lon-
ger than 5 months (range: 3-9), 5 patients (33%) expe-
rienced long-term response lasting up to a median of
22 months (range: 4-46). Concerning those 12 patients
who underwent CD41 treatment only, the response
rate was 75% (8/12 patients). Notably, both patients
with delayed immune recovery associated with therapy
refractory HSV infection achieved clinical response
after application of lower doses of CD41-selected cells
(Table 2). Thus, low-dose CD41 DLIs might be able
to improve antiviral response in the posttransplant
period. This approach needs to be further evaluated
for severe posttransplant complications, for example,
Epstein-Barr virus-related posttransplant lymphopro-
liferative disease.
Historically, effective use of DLIs was first postu-
lated in CML patients [5]. The patients in chronic
phase showed better responses (75%) than those in ac-
celerated/blast phase (range: 12.5%-33%) [36]. Re-
garding the other hematologic entities, responses
were demonstrated less frequently [37]. The median
overall response rate to unmanipulated DLIs was
51% (range: 32%-68%) in previously published studies
summarizing different acute and chronic leukemias. In
these studies, higher response rates of DLIs were seen
in CML patients (76%; range: 59%-100%) compared
to other disorders such as acutemyelogenous leukemia,
acute lymphoblastic leukemia, MDS, or MF (28%;
Biol Blood Marrow Transplant 17:374-383, 2011 381CD4+ T Cells for Posttransplant Immunotherapyrange: 9%-43%) [4,37-43]. Thus, considering the
heterogeneous cohorts of the previous studies on
DLIs (including in the majority as well as acute
leukemia patients), a direct comparison of our data
from this series with previous results is difficult,
because our study focused on patients with chronic
lymphatic and myelogenous disorders. Nevertheless,
our study supports the hypothesis that CD41 DLIs
might induce a GVL effect. Moreover, it is still
possible that other immune cell subpopulations
might as well be relevant. In line, studies in CML
have shown that CD41 DLIs can result in the clonal
expansion of donor-derived T cell clones with specific
antihost (eg, toward the minor histocompatibility anti-
gens) and anti-infectious activity [44,45]. Further,
a subset of CD41CD251FoxP31 regulatory T cells
might play an important role for the outcomes
of HSCT because of an exertion of a potent
immunosuppressive effect and prevent GVHD while
preserving the GVL effect [46].
Considering the frequency of GVHD, we ob-
served aGVHD grade II-IV in 17%, grade III-IV in
8%, limited cGVHD in 8%, and extensive cGVHD
in 4% of patients. Thus, we observed lower GVHD
rates when compared to previous reports on the appli-
cation of uDLIs [4,10,37-43]. In these studies, the
median rate of aGVHD and cGVHD was 36%
(range: 13%-64%) and 37% (range: 6%-76%),
although the majority of patients in these reports had
received matched related HSCT. Although the
optimal cell dose that contributes to the development
of GVL without initiation of a severe GVHD is
indefinite and seems to depend on the underlying
hematologic entity [36], there is some evidence that
a lower T cell dose could be associated with lower
GVHD incidence [6,7,47]. For instance, Mackinnon
et al. [7] used low-dose uDLIs (median CD31 dose 1
 107/kg bw, range: 1  105-1  108) in 22 CML pa-
tients at hematologic relapse of chronic or accelerated
phase (n 5 14), cytogenetic relapse (n 5 6), or molec-
ular relapse (n5 2). The patients receiving lower doses
of DLIs (1  107 CD31/kg bw) experienced less
GVHD (1/21, 5%) as those undergoing high-dose
($1 108 CD31/kg bw) infusions (5/17, 29%). How-
ever, the response rates were similar in both groups (8/
21, 38% versus 7/17, 41%). Therefore, the lower
CD41-cell dose in our study might be crucial in the
lower incidence of GVHD.
Of note, in our study, 13 of 16 patients (81%) who
had a history of aGVHDgrade II-IV or cGVHDeither
after HSCT or after previously administered uDLIs,
developed no GVHD after the first application of
CD41-selected DLIs. There seemed to be a trend to
a higher frequency of aGVHD than cGVHD after
the first CD41 application in our study (17% versus
8%), which was similar to previous results from studies
using CD81-depleted DLIs [12,48]. In addition, weobserved an association between the presence of
GVHD and response to CD41 DLI therapy. Several
mechanisms could be decisive in this setting: (1)
CD41-derived cytokine production (eg, IL-6 or IL-
17) [48-50]; (2) CD41-mediated activation of host
CD81 cells [49]; (3) presence of CD41CD81 double-
positive cells [28]. In contrast, 8 patients showing fail-
ure to CD41 DLIs experienced neither aGVHD nor
cGVHD.
There is already some evidence in the literature that
CD81-depleted DLIs are associated with a reduced
GVHD risk in comparison to uDLIs [14,16,50].
However, in most of those trials some GVHD was
noted, probably because of the applied CD81
depletion methods with considerable amounts of
residual CD81 cells. Moreover, some investigators
reported that CD41-mediated GVHD can occur after
delayed DLIs because of expression of host antigens
by professional hematopoietic cells rather than
parenchymal cells, which were especially observed
after RIC-HSCT [51-53].
When we compared the results from our study
with other reports on use of CD81-depleted infusions,
the rate of GVHD in our study was slightly higher. For
instance, Meyer et al. [14] observed the rate of both
aGVHD grade II-III and cGVHD only in 2 of 23 pa-
tients (9%) following CD81-depleted DLIs [14].
However, because the patients from this study received
alemtuzumab as part of GVHD-prophylaxis to deplete
monocyte-derived dendritic cells that also express
CD52 antigen [54], a direct comparison of our data
with the results from Meyer et al. [14] seems to be
difficult.
We conclude that the CliniMACS device provides
a rapid and selectivemethod to enrichCD41 cells from
donor apheresis products. Administration of DLIs se-
lected for CD41 cells was associated with a relatively
low incidence of aGVHD and cGVHD. This could
be rather related to lower median cell dose being used
in this study. At the same time graft-versus-tumor,
graft-versus-infection, and graft-versus-hematopoiesis
effects seemed to be retained. Considering the limited
number of patients and their heterogeneity, it seems
highly important to further explore the approach of
CD41 enriched DLIs in different hematologic entities
in combinationwith other therapeutic approaches or as
monotherapy in future studies.ACKNOWLEDGMENTS
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